Harnessing ATR Inhibition With Low-Dose Chemotherapy to Deliver Durable Responses in ATM-Deficient Tumors

• Sharing preclinical and translational data on ATR inhibition in ATM-deficient cancers

• Presenting clinical results from Phase I showing strong efficacy, including a 50% objective response rate

• Highlighting the differentiated strategy of combining ATR inhibition with low-dose chemotherapy to overcome past limitations of monotherapy

• Showcasing patient vignettes and narratives to illustrate real-world impact and translational success

Speakers:

Graeme Smith

Chief Scientific Officer

Artios Pharma

Ian Smith

Chief Medical Officer

Artios Pharma